Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs (NCT04943588) | Clinical Trial Compass
CompletedNot Applicable
Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
Pakistan25,000 participantsStarted 2021-11-01
Plain-language summary
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.
Who can participate
Age range
18 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults over 18yrs old
* Willing to undergo hepatitis C testing
* Able and willing to give informed consent
* Willing to return in 12 months time for repeat testing
* Resident in area and not planning to leave the region
Exclusion Criteria:
* Unwilling to give consent
* Unwilling or unable to undergo the necessary procedures
* Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol.
* Co-morbidities limiting life expectancy to less than 12 months
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is based in Pakistan and seems focused on a population-level strategy — is this study actually accessible and relevant to my situation, or is it designed for a specific community or setting that may not apply to me?
2The trial is measuring SVR, which I understand means the virus is undetectable after treatment — can you explain what achieving SVR would realistically mean for my long-term liver health, and how the strategies being tested here compare to standard treatment I could get right now?
3Since this trial is also tracking re-infection rates, does that mean participants may be at ongoing risk of getting hepatitis C again during the study, and how would that affect my health if it happened?
4The trial is listed as Phase NA, which I'm not familiar with — can you help me understand what that means for how much is already known about the safety and effectiveness of the approaches being used in this study?
5Given that this study seems focused on avoiding drug resistance, are there concerns that the treatment approach I'd receive in standard care might lead to resistance, and is that something worth factoring into the decision about whether a trial like this could be worth discussing further?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.